Leo Wealth LLC Acquires 155,512 Shares of Kenvue Inc. $KVUE

Leo Wealth LLC bought a new position in Kenvue Inc. (NYSE:KVUE) during the third quarter, HoldingsChannel.com reports. The fund bought 155,512 shares of the company’s stock, valued at approximately $2,746,000.

Several other institutional investors and hedge funds have also made changes to their positions in the business. BlackRock Inc. purchased a new stake in shares of Kenvue during the second quarter valued at $2,882,279,000. Pentwater Capital Management LP bought a new position in shares of Kenvue in the second quarter worth about $977,094,000. HBK Investments L P grew its holdings in shares of Kenvue by 33.3% in the second quarter. HBK Investments L P now owns 28,000,001 shares of the company’s stock worth $535,080,000 after purchasing an additional 7,000,000 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in Kenvue by 0.9% in the 1st quarter. Dimensional Fund Advisors LP now owns 22,270,175 shares of the company’s stock worth $383,938,000 after buying an additional 196,981 shares during the period. Finally, Amundi increased its stake in Kenvue by 41.2% in the 2nd quarter. Amundi now owns 18,483,326 shares of the company’s stock worth $353,216,000 after buying an additional 5,392,413 shares during the period. 97.64% of the stock is currently owned by institutional investors.

Kenvue Price Performance

Shares of KVUE stock opened at $19.48 on Tuesday. Kenvue Inc. has a twelve month low of $14.02 and a twelve month high of $20.13. The stock has a market capitalization of $37.43 billion, a price-to-earnings ratio of 16.58, a P/E/G ratio of 1.79 and a beta of 0.48. The stock has a fifty day simple moving average of $18.36 and a two-hundred day simple moving average of $18.12. The company has a current ratio of 1.01, a quick ratio of 0.71 and a debt-to-equity ratio of 0.67.

Kenvue (NYSE:KVUE) last posted its quarterly earnings results on Thursday, August 6th. The company reported $0.31 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.01). The firm had revenue of $3.96 billion for the quarter, compared to the consensus estimate of $3.97 billion. Kenvue had a return on equity of 21.22% and a net margin of 10.76%. Kenvue’s quarterly revenue was up 3.0% compared to the same quarter last year. During the same period in the previous year, the company posted $0.29 EPS. On average, analysts predict that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, October 2nd. Investors of record on Monday, September 21st were issued a $0.21 dividend. This represents a $0.84 annualized dividend and a dividend yield of 4.3%. The ex-dividend date was Monday, September 21st. Kenvue’s payout ratio is presently 96.55%.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the stock. Zacks Research lowered shares of Kenvue from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 7th. Barclays upped their target price on shares of Kenvue from $18.00 to $19.00 and gave the stock an “equal weight” rating in a research note on Tuesday, July 21st. Weiss Ratings restated a “hold (c)” rating on shares of Kenvue in a research note on Friday, September 11th. UBS Group reduced their target price on shares of Kenvue from $20.00 to $19.00 and set a “neutral” rating on the stock in a research report on Tuesday, August 11th. Finally, Wall Street Zen downgraded shares of Kenvue from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Ten investment analysts have rated the stock with a Hold rating. According to data from MarketBeat.com, Kenvue presently has an average rating of “Hold” and an average target price of $18.50.

About Kenvue

Kenvue Inc is a consumer health company that develops, markets and sells products designed to support everyday health and personal care. Its portfolio spans over-the-counter medicines, skin health and beauty, and essential health products, serving consumers through retail, e-commerce and other distribution channels.

The company’s brands include Tylenol, Motrin, Zyrtec and Benadryl in self-care; Neutrogena, Aveeno and Clean & Clear in skin health and beauty; and Listerine, Johnson’s and OGX in oral care, baby care and hair care.